{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:05:15Z","timestamp":1766361915412,"version":"3.44.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bulcan.2021.03.017","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T15:47:36Z","timestamp":1622044056000},"page":"730-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cancer du sein et microangiopathies thrombotiques paran\u00e9oplasiques"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3826-4039","authenticated-orcid":false,"given":"Marion","family":"Alhenc-Gelas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-8949","authenticated-orcid":false,"given":"Fran\u00e7ois-Cl\u00e9ment","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bulcan.2021.03.017_bib0325","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.1962.tb06541.x","article-title":"Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis","volume":"8","author":"Brain","year":"1962","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.bulcan.2021.03.017_bib0330","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bulcan.2021.03.017_bib0335","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.revmed.2017.06.025","article-title":"Microangiopathies thrombotiques secondaires","volume":"38","author":"Coppo","year":"2017","journal-title":"Rev Med Interne"},{"issue":"6","key":"10.1016\/j.bulcan.2021.03.017_bib0340","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","article-title":"Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111\u00a0cases","volume":"98","author":"Veyradier","year":"2001","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2021.03.017_bib0345","first-page":"594","article-title":"Microangiopathies thrombotiques\u00a0: physiopathologie, diagnostic et traitement","volume":"14","author":"Coppo","year":"2005","journal-title":"Reanim"},{"issue":"2","key":"10.1016\/j.bulcan.2021.03.017_bib0350","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2141.1970.tb01433.x","article-title":"Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma","volume":"18","author":"Brain","year":"1970","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bulcan.2021.03.017_bib0355","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00005792-197909000-00004","article-title":"Microangiopathic hemolytic anemia and cancer: a review","volume":"58","author":"Antman","year":"1979","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.bulcan.2021.03.017_bib0360","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000335201","article-title":"Breast cancer-associated thrombotic microangiopathy","volume":"6","author":"Regierer","year":"2011","journal-title":"Breast Care"},{"issue":"3","key":"10.1016\/j.bulcan.2021.03.017_bib0365","doi-asserted-by":"crossref","first-page":"368","DOI":"10.7326\/0003-4819-79-3-368","article-title":"Microangiopathic hemolytic anemia in metastatic carcinoma: report of eight cases","volume":"79","author":"Lohrmann","year":"1973","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.bulcan.2021.03.017_bib0370","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168\u00a0reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bulcan.2021.03.017_bib0375","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0609.2010.01448.x","article-title":"Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration: cancer-associated microangiopathic hemolytic anemia with thrombocytopenia","author":"Elliott","year":"2010","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.bulcan.2021.03.017_bib0380","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2217\/fon.14.113","article-title":"Metastatic cancer-related thrombotic microangiopathies: a cohort study","volume":"10","author":"Ducos","year":"2014","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0385","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13058-021-01386-y","article-title":"Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study","volume":"23","author":"Alhenc-Gelas","year":"2021","journal-title":"Breast Cancer Res BCR"},{"issue":"5","key":"10.1016\/j.bulcan.2021.03.017_bib0390","first-page":"510","article-title":"Syndromes de microangiopathie thrombotique et oncologie","volume":"22","author":"Tadros","year":"2013","journal-title":"Reanim"},{"issue":"2","key":"10.1016\/j.bulcan.2021.03.017_bib0395","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0400","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00280-008-0900-x","article-title":"Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report","volume":"64","author":"Bharthuar","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.bulcan.2021.03.017_bib0405","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jvir.2008.10.025","article-title":"Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab","volume":"20","author":"Onitilo","year":"2009","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"10.1016\/j.bulcan.2021.03.017_bib0410","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: analysis of 85\u00a0cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2021.03.017_bib0415","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2169\/internalmedicine.40.237","article-title":"Hemolytic uremic syndrome with intracranial hemorrhage following mitomycin C administration","volume":"40","author":"Nishiyama","year":"2001","journal-title":"Intern Med Tokyo Jpn"},{"issue":"2","key":"10.1016\/j.bulcan.2021.03.017_bib0420","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/08860228709056324","article-title":"Hemolytic-uremic syndrome and acute renal failure in metastatic adenocarcinoma treated with mitomycin: case report and literature review","volume":"10","author":"D\u2019Elia","year":"1987","journal-title":"Ren Fail"},{"issue":"5","key":"10.1016\/j.bulcan.2021.03.017_bib0425","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00001813-199806000-00010","article-title":"Mitomycin C-related hemolytic uremic syndrome in cancer patients","volume":"9","author":"Schiebe","year":"1998","journal-title":"Anticancer Drugs"},{"issue":"4","key":"10.1016\/j.bulcan.2021.03.017_bib0430","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.017_bib0435","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fmed.2020.00212","article-title":"An update in drug-induced thrombotic microangiopathy","volume":"7","author":"Chatzikonstantinou","year":"2020","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.bulcan.2021.03.017_bib0440","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/1078155219887212","article-title":"Pembrolizumab-induced thrombotic thrombocytopenic purpura","volume":"26","author":"Dickey","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.bulcan.2021.03.017_bib0445","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-017-0224-7","article-title":"Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)","volume":"5","author":"King","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2021.03.017_bib0450","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.clbc.2017.10.001","article-title":"Palbociclib-induced thrombotic microangiopathy in metastatic breast cancer patient surviving for 18\u00a0years: case report and review of the literature","volume":"18","author":"Raiss","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"1\u20136","key":"10.1016\/j.bulcan.2021.03.017_bib0455","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2119\/2003-00047.Versteeg","article-title":"Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways","volume":"10","author":"Versteeg","year":"2004","journal-title":"Mol Med Camb Mass"},{"issue":"6","key":"10.1016\/j.bulcan.2021.03.017_bib0460","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.neo.7900263","article-title":"The hypercoagulable state of malignancy: pathogenesis and current debate","volume":"4","author":"Caine","year":"2002","journal-title":"Neoplasia N Y N"},{"issue":"4","key":"10.1016\/j.bulcan.2021.03.017_bib0465","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajh.20783","article-title":"Management of cancer-associated thrombotic microangiopathy: what is the right approach?","volume":"82","author":"Werner","year":"2007","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0470","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00000421-200002000-00021","article-title":"Thrombotic thrombocytopenic purpura in metastatic carcinoma of the breast","volume":"23","author":"von Bubnoff","year":"2000","journal-title":"Am J Clin Oncol"},{"issue":"22","key":"10.1016\/j.bulcan.2021.03.017_bib0475","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bulcan.2021.03.017_bib0480","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000366474","article-title":"Pulmonary tumor thrombotic microangiopathy induced by ureteral carcinoma: a necropsy case report","volume":"7","author":"Marumo","year":"2014","journal-title":"Case Rep Oncol. mai"},{"issue":"9","key":"10.1016\/j.bulcan.2021.03.017_bib0485","first-page":"2244","article-title":"Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies","volume":"59","author":"Oleksowicz","year":"1999","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bulcan.2021.03.017_bib0490","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1172\/JCI200318882","article-title":"Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas","volume":"112","author":"Wahrenbrock","year":"2003","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.bulcan.2021.03.017_bib0495","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JOP.2016.012096","article-title":"Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer","volume":"12","author":"Morton","year":"2016","journal-title":"J Oncol Pract"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0500","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2141.2001.02704.x","article-title":"Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease","volume":"113","author":"Fontana","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bulcan.2021.03.017_bib0505","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2141.2008.07575.x","article-title":"Microangiopathic haemolytic anaemia in a patient with metastatic breast cancer","volume":"146","author":"Himmelmann","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bulcan.2021.03.017_bib0510","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/(SICI)1096-8652(199908)61:4<254::AID-AJH5>3.0.CO;2-C","article-title":"Microangiopathic hemolytic anemia associated with metastatic breast carcinoma","volume":"61","author":"Ataga","year":"1999","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.bulcan.2021.03.017_bib0515","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","author":"Oberic","year":"2009","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.bulcan.2021.03.017_bib0520","first-page":"169","article-title":"Microangiopathic haemolytic anaemia with advanced breast carcinoma: improvement with chemotherapy","volume":"28","author":"Rodenburg","year":"1985","journal-title":"Neth J Med"},{"issue":"26","key":"10.1016\/j.bulcan.2021.03.017_bib0525","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198406283102608","article-title":"Case 26-1984: microangiopathic hemolytic anemia in a 53-year-old woman with metastatic breast cancer","volume":"310","author":"Cabot","year":"1984","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0530","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s40064-016-2312-4","article-title":"Microangiopathic hemolytic anemia associated with metastatic breast cancer: case report and literature review","volume":"5","author":"Takabatake","year":"2016","journal-title":"SpringerPlus"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0535","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02967054","article-title":"A case of microangiopathic hemolytic anemia associated with breast cancer: improvement with chemoendocrine therapy","volume":"4","author":"Narita null","year":"1997","journal-title":"Breast Cancer Tokyo Jpn"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0540","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.12-1-11","article-title":"Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10\u00a0patients and a systematic review of published cases","volume":"12","author":"Francis","year":"2007","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bulcan.2021.03.017_bib0545","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nephro.2017.01.023","article-title":"Thrombotic microangiopathy and cancer","volume":"13","author":"Kheder El-Fekih","year":"2017","journal-title":"Nephrol Ther"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0550","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0555","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13256-017-1373-5","article-title":"Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report","volume":"11","author":"Facchini","year":"2017","journal-title":"J Med Case Rep"},{"issue":"6","key":"10.1016\/j.bulcan.2021.03.017_bib0560","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/00007611-199506000-00021","article-title":"Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary origin","volume":"88","author":"Lin","year":"1995","journal-title":"South Med J"},{"issue":"4","key":"10.1016\/j.bulcan.2021.03.017_bib0565","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1634\/theoncologist.8-4-375","article-title":"Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer","volume":"8","author":"Chang","year":"2003","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bulcan.2021.03.017_bib0570","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00063-004-1023-8","article-title":"Severe microangiopathic hemolytic anemia as first manifestation of a CUP syndrome. Rapid hematologic remission under polychemotherapy","volume":"99","author":"Abdel Samie","year":"2004","journal-title":"Med Klin Munich Ger"},{"issue":"3","key":"10.1016\/j.bulcan.2021.03.017_bib0575","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.critrevonc.2014.07.003","article-title":"Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?","volume":"92","author":"Guiu","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bulcan.2021.03.017_bib0580","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","article-title":"Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort","volume":"96","author":"Gobbini","year":"2018","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000495031","article-title":"Treatment of chemotherapy-induced thrombotic microangiopathy with eculizumab in a patient with metastatic breast cancer","volume":"12","author":"Hausberg","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.bulcan.2021.03.017_bib0590","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4137\/BCBCR.S14920","article-title":"Successful remission of hemolytic-uremic syndrome during the third-line weekly gemcitabine for metastatic breast cancer","volume":"8","author":"Kok","year":"2014","journal-title":"Breast Cancer Basic Clin Res"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0595","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.4081\/hr.2014.5159","article-title":"Isolated hemolytic anemia: an unusual manifestation of occult malignancy","volume":"6","author":"Butler","year":"2014","journal-title":"Hematol Rep"},{"issue":"2","key":"10.1016\/j.bulcan.2021.03.017_bib0600","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12032-013-0568-x","article-title":"Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report","volume":"30","author":"Iams","year":"2013","journal-title":"Med Oncol Northwood Lond Engl"},{"issue":"34","key":"10.1016\/j.bulcan.2021.03.017_bib0605","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1200\/JCO.2011.36.7433","article-title":"Thrombotic microangiopathy and disseminated intravascular coagulation associated with carcinocythemia in a patient with breast cancer","volume":"29","author":"Robier","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2021.03.017_bib0610","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3109\/0284186X.2010.491088","article-title":"Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma","volume":"50","author":"Willemsen AECAB","year":"2011","journal-title":"Acta Oncol Stockh Swed"},{"issue":"4","key":"10.1016\/j.bulcan.2021.03.017_bib0615","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s12032-009-9333-6","article-title":"Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report","volume":"27","author":"Siau","year":"2010","journal-title":"Med Oncol Northwood Lond Engl"},{"issue":"12","key":"10.1016\/j.bulcan.2021.03.017_bib0620","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.20290","article-title":"Gemcitabine-associated thrombotic microangiopathy","volume":"100","author":"Humphreys","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2021.03.017_bib0625","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/annonc\/mdh478","article-title":"Zoledronic acid-associated thrombotic thrombocytopenic purpura","volume":"15","author":"Ferretti","year":"2004","journal-title":"Ann Oncol"},{"issue":"2B","key":"10.1016\/j.bulcan.2021.03.017_bib0630","first-page":"1183","article-title":"Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: a case report","volume":"22","author":"Citarrella","year":"2002","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.017_bib0635","first-page":"193","article-title":"Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer","volume":"18","author":"Fisher","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"30","key":"10.1016\/j.bulcan.2021.03.017_bib0320","first-page":"2300","article-title":"Thrombotic microangiopathy and chronic renal failure caused by mitomycin C in 4\u00a0women treated for breast cancer","volume":"11","author":"Bayle","year":"1982","journal-title":"Nouv Presse Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121001831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121001831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:34:28Z","timestamp":1757792068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121001831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":64,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0007455121001831"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.03.017","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer du sein et microangiopathies thrombotiques paran\u00e9oplasiques","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}